BSE: 532660 | NSE: VIVIMEDLAB | Pharmaceuticals & Drugs | Small Cap
1. Is Vivimed Labs Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Vivimed Labs Ltd is a average quality company.
2. Is Vivimed Labs Ltd undervalued or overvalued?
The key valuation ratios of Vivimed Labs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
3. Is Vivimed Labs Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vivimed Labs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||7.5%||6%||6.8%||4.8%||16.4%||4.7%||4.5%||1.9%||0.7%||-4.8%||-|
|Value Creation Index ⓘ||-0.5||-0.6||-0.5||-0.7||0.2||-0.7||-0.7||-0.9||-1.0||-1.3||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||2.1%||-0.4%||-25.8%||78.4%||-54.1%||-3.7%||9.9%||-24.1%||4%||-|
|Adj EPS ⓘ||4.1||2.4||2.9||0.9||16.2||1.6||0.8||-1.7||-2.8||-8.2||-9.9|
|YoY Gr. Rt. %||-||-41.3%||21%||-71.1%||1803.5%||-90.2%||-52.5%||-321.3%||NA||NA||-|
|BVPS (₹) ⓘ||42.7||45.8||46||45.5||64.5||64.2||64.8||62.2||58.7||50.6||43|
|Adj Net Profit ⓘ||33.2||19.7||23.8||6.9||131||13.1||6.2||-13.8||-23.3||-67.8||-82|
|Cash Flow from Ops. ⓘ||44.2||-44.9||41.3||-54.2||28.2||207||82||75||180||25.3||-|
|Debt/CF from Ops. ⓘ||10||-14.2||16.9||-11.1||20.3||2.2||4.2||4.1||1.8||14.1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-207.9%||-187.2%||-321.7%||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||9.6||5.5||6.4||1.9||28.2||2.3||1.1||-2.4||-4.3||-13.8||-21.1|
|Op. Profit Mgn % ⓘ||21.7||21.8||27.2||27.2||45.2||31.7||26.8||14.6||13.3||-4.1||-13.7|
|Net Profit Mgn % ⓘ||7.9||4.6||5.5||2.2||23||5||2.5||-5||-11.1||-31||-43|
|Debt to Equity ⓘ||1.3||1.7||1.9||1.6||1.1||0.8||0.7||0.6||0.7||0.9||-|
|Working Cap Days ⓘ||332||414||496||754||470||986||902||752||865||742||0|
|Cash Conv. Cycle ⓘ||164||230||297||486||281||608||568||435||523||474||0|
Debt to equity has declined versus last 3 years average to 0.85
Return on Equity is Poor
Sales growth has been subdued in last 3 years -4.64%
Sales growth is not so good in last 4 quarters at 0.84%
|TTM EPS (₹)||-9.9||-9.8|
|TTM Sales (₹ Cr.)||190||211|
|BVPS (₹.) ⓘ||43||31.8|
|Reserves (₹ Cr.) ⓘ||340||247|
|From the Market|
|52 Week Low / High (₹)||6.67 / 17.37|
|All Time Low / High (₹)||6.44 / 153.30|
|Market Cap (₹ Cr.)||55.3|
|Equity (₹ Cr.)||16.6|
|Face Value (₹)||2|
|Industry PE ⓘ||36.2|
Vivimed Labs Ltd was originally incorporated as Emgi Pharmaceuticals & Chemicals Private Limited on 22-09-1988 with Registrar of Companies of Karnataka, Bangalore and subsequently converted into a public limited company on April 21, 1994. The name of the company has been changed to Vivimed Labs Limited on April 22,1997.
The company was originally promoted by A. M. Rao. In 1989 Santosh Varalwar and Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Limited and commenced manufacturing of bulk drugs in 1991.
The companyâ€™s manufacturing unit is located at Bidar, Karnataka, where it was originally engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs like Ibuprofen etc. However, due to downward price movement in the products of the company during 1995, it gradually moved over to manufacturing specialty chemicals and cosmetic ingredients like Triclosan, Avis etc. catering to global and domestic markets.
Vivimed started production of Triclosan with a very small capacity of 5 MT p.a. in the year 1999 and increased its capacity to 225 MT p.a. over a period of next 5 years. The production capacity was further doubled by adding one more production block in March 2004.
Touching lives on another front, they are fighting microbes in home. In the kitchen, in the linen and more, their antimicrobials deliver clean living. Their high-end chemistry also coats the screen of mobile telephone and carâ€™s photochromatic windscreen. For the photographic industry they remain a timeless answer. Their photosynthetic and photographic chemicals have been products of choice for decades now.
Product range of the company includes:
1988 & 1989â€¢ Incorporated on September 22, 1988â€¢ Death of original promoter Mr. A. M. Raoâ€¢ Acquired by Mr. Santosh Varalwar and Mr. Subhash Varalwar
1990 â€¢ Commenced production of Non-Steroidal Anti-Inflammatory Drug (NSAID) â€“ IBUPROFEN.
1994 â€¢ Diversification and expansion of product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal).
1995 â€¢ Diversification into specialty chemicals by production of Triclosan.
1996 â€¢ R&D was commenced with facilities having an integrated instrumentation for organicsynthesis, Microbiology and pre-formulation studies.
1997 â€¢ Process Innovation of Anti-bacterial and clearance of innovative route of synthesis for Triclosan.â€¢ Grant of patent for VIV-20 (Triclosan) by the Indian Patents Office.1998 â€“ 99â€¢ Qualified for supply to Unileverâ€™s Asian locations after Audit of manufacturing facility by a team of Unilever Plc.â€¢ Triclosan customer base expanded to UK, France, Germany as well as domestic market.
2002 â€¢ Approved by Unilever group Companies in Asian/Middle & Far East Companies for usage of Enamel Protective Agent manufactured by the company in their oral care formulations.â€¢ Developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends.â€¢ Vivimed emerges as a second chemical company located outside USA/Europe to get the US EPAâ€™s registration for Triclosan as 99% ingredient.â€¢ Vivimedâ€™s Quality Management System gets ISO 9001:2000 certification.
2003 â€¢ Signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123.â€¢ Commencement of EMS Audit for ISO 14001 certification.
2004 â€¢ Introduced new products for anti-dandruff and skin care applicationâ€¢ Triclosan production capacity increased from 225 MT p.a. to 480 MT p.a.â€¢ Developed novel synthetic process to manufacture a premium anti-oxidant and anti-cancer molecule branded as VINTOX
2012 â€¢ Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona.
2013â€¢ Vivimed Labs Limited signed an agreement to acquire Actavis Pharma Manufacturing Pvt. Ltd.â€™s solid oral dosage (â€œSODâ€) facility in Alathur, Tamil Nadu, India. The facility acquired from its parent Actavis Holding Asia B.V., an affiliate of Actavis Inc.
2014 â€¢ Vivimed received the PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) GMP (Good Manufacturing Practice) approval for one of its pharmaceuticals manufacturing facilities in Jeedimetla, Hyderabad for the supply of finished dosage formulations to the CIS (Commonwealth of Independent States) region.